Transport and logistics company, Kuehne + Nagel, has entered an international supply chain agreement to store and distribute Moderna’s Covid-19 vaccine.
This announcement follows the granting of conditional marketing authorisation by the European Medicines Agency (EMA) for Covid-19 Vaccine Moderna.
Kuehne + Nagel will support the worldwide distribution of vaccine doses from Moderna’s international supply chain, based in Europe. This includes distribution to markets in Europe, Asia, Middle East and Africa and parts of the Americas.
“We are proud to be partnering with Kuehne + Nagel from Europe to support the distribution of vaccines to global citizens,” said Moderna Vice President Head of EMEA Region, Dan Staner.
The arrangement includes distribution and warehousing of the vaccine from Kuehne + Nagel’s pharma hub in Europe. Kuehne+Nagel will use its network of more than 230 operations worldwide to distribute the vaccine via road and air. In Europe alone, the company operates its own fleet of over 200 dedicated pharmaceutical transport vehicles. At all stages of transport and storage, product integrity at the required temperature of -20°C will be maintained.
Kuehne + Nagel has more than 230 good practice certification in the pharmaceutical industry (GxP) operations worldwide, including Australia, and last year opened airside pharma and healthcare hubs in Brussels, Belgium, and Johannesburg, South Africa.